Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

NCT03363217 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Low-grade Glioma
Plexiform Neurofibroma
Central Nervous System Glioma

Interventions

DRUG: Trametinib

Sponsor

St. Justine's Hospital

Collaborators

[object Object]
[object Object]